AULT MILTON C III 4

What Happened

• Milton C. Ault III, a director of Alzamend Neuro, purchased 108,388 shares of ALZN in an open-market transaction on April 14, 2026. The reported price was $1.00 per share for a total reported acquisition value of $108,897.
• This was a purchase (P), which investors often view as a more informative insider action than routine sales, though it does not by itself indicate the insider’s motives.

Key Details

• Transaction date and price: 2026-04-14 at $1.00 per share.
• Shares acquired: 108,388; reported total value: $108,897.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed on 2026-04-16 (appears timely given the 2-business-day reporting requirement).
• Notable footnotes:
  • F1: Ault Lending, LLC is a wholly-owned subsidiary of Hyperscale Data, Inc.; Milton Ault is deemed to have voting and investment power over securities held by Ault Lending.
  • F2–F3: Mr. Ault has sole voting and investment power for securities held by Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC.

Context

• The transaction code P indicates a straight purchase (open-market buy). No options exercise, grant, or gift was reported here.
• The filing ties Mr. Ault to several related entities that may hold additional ALZN shares; these footnotes clarify where voting/investment power resides but do not change the fact of this direct purchase.